Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05769621 · ClinicalTrials.gov registry record

A Retrospective Study to Characterize Participants With Propionic Acidemia

A clinical trial of Propionic Acidemia, sponsored by ModernaTX.

Recruiting
Registry status
60
Enrollment target
20
Study locations

NCT05769621 is a study of Propionic Acidemia that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 60 participants, below the 215-participant average among 6 other Propionic Acidemia trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 20 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05769621, a study of Propionic Acidemia, is actively recruiting participants, sponsored by ModernaTX.

RECRUITING
Registry status
60 participants
Enrollment target
20
Study locations

Study Summary

This is a non-interventional, observational, global, multicenter, study describing participant characteristics, clinical outcomes, and event rates in participants with propionic acidemia (PA).

Conditions Studied

Study Locations (20)

California

  • University of Stanford Medical Center - Stanford

Maryland

  • Johns Hopkins University - Baltimore

Michigan

  • University of Michigan Hospital - Ann Arbor

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Texas

  • Texas Children's Hospital - Houston

Washington

  • Seattle Children's Hospital - Seattle

Victoria

  • Royal Children's Hospital Melbourne - Parkville

Alberta

  • Stollery Children's Hospital University of Alberta - Edmonton

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-06-16
Est. Completion 2026-09-30

Sponsor

ModernaTX

90 total trials

What the Registry Record Tells You About NCT05769621

The ClinicalTrials.gov registry entry for NCT05769621 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 6 other Propionic Acidemia trials with a reported enrollment target (72% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Propionic Acidemia appearing as the primary indexed condition, and to 0 interventions.

NCT05769621 reports 20 study locations spanning 20 distinct geographic areas - top geographies include California, Maryland, Michigan.

Frequently Asked Questions

What is clinical trial NCT05769621 about?

NCT05769621 is a clinical study titled "A Retrospective Study to Characterize Participants With Propionic Acidemia". This is a non-interventional, observational, global, multicenter, study describing participant characteristics, clinical outcomes, and event rates in participants with propionic acidemia (PA).

What is the current status of trial NCT05769621?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2023-06-16. Estimated completion is 2026-09-30.

What conditions does trial NCT05769621 study?

This clinical trial studies the following conditions: Propionic Acidemia.

Who is sponsoring clinical trial NCT05769621?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05769621 being conducted?

This trial has 20 study locations across California, Maryland, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Propionic Acidemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.